VR Logo

Cyclo Therapeutics Inc. (CYTH) download report


Healthcare | Drugs & Pharma

Cyclo Therapeutics Inc. (CYTH) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases.

IPO Date: 23-Feb-2011

CEO & Director: Mr. N. Scott Fine

Founder & Director: Mr. C. E Strattan

Listing: NASDAQ: CYTH

Country: United States

Headquarters: Gainesville, FL

Website: https://www.cyclotherapeutics.com

Key Facts

Market cap: $19.11 Mln

Revenue (TTM): $1.42 Mln

Earnings (TTM): $-13.02 Mln

Cash: $11.80 Mln

Total Debt: $0.01 Mln

Insider's Holding: 9.33%

Liquidity: Low

52 Week range: $1.82 - 8.45

Shares outstanding: 8,416,550

6 Years Aggregate:

  • CFO: $-39.34 Mln
  • EBITDA: $-38.79 Mln
  • Net Profit: $-43.07 Mln

Stock Performance

Time Period Cyclo Therapeutics (CYTH) S&P BSE Healthcare* S&P Small-Cap 600*
YTD-38.34-11.28-11.58
1 month13.865.328.86
3 months-10.161.46-2.19
1 Year-71.88-11.83-6.23
3 Years-54.2422.759.73
5 Years-42.3810.857.72
10 Years-19.3712.2710.81
As on 05-Aug-2022 *As on 08-Aug-2022
Year Cyclo Therapeutics (CYTH) S&P Small-Cap 600 S&P BSE Healthcare
2021-14.2525.2720.87
2020-87.219.5761.45
2019-57.1020.86-3.55
2018128.57-9.70-5.89
2017-18.6011.730.49
2016-21.8224.74-12.88
2015-14.06-3.3615.06